Searched for
CAGRISEMA TRIAL UNDERPERFORMANCE
US Stocks | Wall Street ends sharply lower amid AI displacement fears and revived tariff angstA broad selloff sent all three major U.S. stock indexes more than 1% lower by the closing bell, as risk appetite was dampened by a combinat...- S&P 500, Dow Jones, Nasdaq crash at U.S Stock Market. Top gaining, losing stocks at Wall StreetU.S Stock Market today: On Wall Street, big losses hit companies under suspicion of getting undercut by AI-powered rivals. Investors have b...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
- Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped outNovo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects futur...
Load More